Physician profile
Rhonda Shryock
NPI 1063827400
$4,351.53
in general payments reported to CMS, 2019-2025
22 companies · $1,175 in 2025
The $1,175 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $259 · 2022: $800 · 2023: $1,138 · 2024: $979 · 2025: $1,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,077 · Education: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,076.97 |
| Education | $214.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $769.50 | 2021-2025 | |
| Janssen Biotech, INC. | $609.80 | 2022-2025 | Tremfya, Simponi Aria, Remicade |
| Amgen INC. | $607.07 | 2021-2025 | Tavneos, Enbrel, Evenity |
| Novartis Pharmaceuticals Corporation | $387.80 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $258.08 | 2021-2025 | Saphnelo |
| Pfizer INC. | $246.89 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $193.62 | 2021-2025 | Orencia |
| Ucb, INC. | $182.22 | 2022-2025 | Cimzia, Bimzelx |
| Mallinckrodt Hospital Products INC. | $181.58 | 2022-2025 | Acthar |
| Glaxosmithkline, LLC. | $180.84 | 2021-2025 | Benlysta |
| Organon LLC | $121.67 | 2021-2025 | Renflexis, Hadlima |
| Lilly USA, LLC | $91.28 | 2023-2025 | Taltz |
| Sandoz INC. | $88.32 | 2024-2025 | Jubbonti, Hyrimoz |
| Alexion Pharmaceuticals, INC. | $81.82 | 2023-2025 | Strensiq |
| Radius Health, INC. | $63.57 | 2023-2025 | Tymlos |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $61.94 | 2024-2025 | Actemra, Gazyva |
| Sobi, INC | $56.62 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.76 | 2023-2024 | Cyltezo |
| Genzyme Corporation | $42.58 | 2023-2024 | |
| Aurinia Pharma U.S., INC. | $41.26 | 2021-2024 | Lupkynis |
| Kiniksa Pharmaceuticals International, Plc | $22.22 | 2024 | Arcalyst |
| Antares Pharma, INC. | $18.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhonda Shryock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.